Bristol-Myers Squibb Company

BMS/Celgene weaponized the FDA-mandated REMS safety program for Revlimid (lenalidomide) as a barrier to generic competition — the most documented case of REMS abuse in US pharmaceutical history. Strategy: (1) denied drug samples to generic manufacturers citing "safety," blocking required FDA bioequivalence testing; (2) filed 206 patents (117 granted) creating a prohibitive thicket; (3) settled with generics under volume caps limiting them to 7% market share years after the primary patent expired in October 2019, with restrictions not fully lifting until January 2026. Price rose from $215/pill (2005) to $763/pill (post-acquisition) — 254% vs 31% CPI inflation. ~$100B lifetime revenue. House Oversight found Celgene rewarded executives with $400M in compensation tied to price increases. Active antitrust lawsuits from Mayo Clinic, Cigna (alleging BMS leveraged Revlimid settlements to extract pay-for-delay on Pomalyst), and class actions.

BMS has ~$3 billion in cumulative regulatory penalties across 52 enforcement records (Violation Tracker). Major actions: $150M SEC settlement (2004) for securities fraud — channel-stuffing that inflated earnings by $1.5B. $515M DOJ settlement (2007) for illegal off-label marketing of Abilify to children, kickbacks to physicians, and fraudulent drug pricing. $75M DOJ False Claims Act settlement (2021) for underpaying Medicaid rebates. $14M SEC settlement (2015) for FCPA violations — China sales reps provided cash, jewelry, and gifts to healthcare providers. $700M Plavix failure-to-warn settlement with Hawaii (2025) — drug ineffective for certain ethnic backgrounds, prescribed 837K+ times. Criminal guilty plea (2007) for perjury regarding Plavix anti-generic agreements.